Inovio Pharmaceuticals disclosed preliminary unaudited cash and cash equivalents of approximately $36.7 million as of June 30, 2026. This figure is based on management estimates and has not been audited or reviewed by Ernst & Young LLP. The company cautioned that actual results may differ materially from these preliminary figures pending the completion of financial closing procedures. Inovio Pharmaceuticals operates in the biotechnology industry, focusing on DNA-based vaccine development.
